3篇
您的检索式：作者名="Flavio Steinwurz"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 2010年世界胃肠病学组织关于炎症性肠病诊断和治疗的实践指南显示文摘炎症性肠病(IBD)是一组特发性、慢性、炎症性肠道疾病状态,包括两种主要类型:克罗恩病(CD)和溃疡性结肠炎(UC),两者的临床和病理特征既有重叠又有区别。IBD过去常见于发达国家,近几十年,发展中国家的患病率逐步上升。本指南就IBD诊断和治疗方面提出的独特议题在当前的文献和指南中几乎从未被提及。由于各地区的IBD临床特点差异较大,因此根据患者的主诉诊断IBD或评估疾病活动度需随地区的变化而变化。同样,治疗亦应根据疾病的分类和当地医疗资源进行调整。世界胃肠病学组织根据世界各国医疗资源的差异,采用级联方法制订了IBD的诊疗指南。 | Charles N.Bernstein Michael Fried J.H.Krabshuis Henry Cohen R.Eliakim Suleiman Fedail Richard Gearry K.L.Goh Saheed Hamid Aamir Ghafor Khan A.W.LeMair Malfertheiner Qin Ouyang J.F.Rey Ajit Sood Flavio Steinwurz Ole O.Thomsen Alan Thomson Gillian Watermeyer 杨钊斌 杨川华 钱本余 | 2010 | 胃肠病学2010，15，9： | 101 |
| 2 | Combination of corticosteroids and 5-aminosalicylates or corticosteroids alone for patients with moderate-severe active ulcerative colitis:A global survey of physicians'practice显示文摘AIM To examine treatment decisions of gastroenterologists regarding the choice of prescribing 5-aminosalycilates(5ASA) with corticosteroids(CS) versus corticosteroids alone for patients with active ulcerative colitis(UC). METHODS A cross-sectional questionnaire exploring physicians' attitude toward 5ASA + CS combination therapy vs CS alone was developed and validated. The questionnaire was distributed to gastroenterology experts in twelve countries in five continents. Respondents' agreement with stated treatment choices were assessed by standardized Likert scale. Background professional characteristics of respondents were analyzed for correlation with responses. RESULTS Six hundred and sixty-four questionnaires were distributed and 349 received(52.6% response rate). Of 340 eligible respondents, 221(65%) would continue 5ASA in a patient hospitalized for intravenous CS treatment due to a moderate-severe UC flare, while 108(32%) would stop the 5ASA(P < 0.001), and 11(3%) are undecided. Similarly, 62% would continue 5ASA in an out-patient starting oral CS. However, only 140/340(41%) would proactively start 5ASA in a hospitalized patient not receiving 5ASA before admission. Most(94%) physicians consider the safety profile of 5ASA as very good. Only 52% consider them inexpensive, 35% perceive them to be expensive and 12% are undecided. On multi-variable analysis, less years of practice and perception of a plausible additive mechanistic effect of 5ASA + CS were positively associated with the decision to continue 5ASA with CS. CONCLUSION Despite the absence of data supporting its benefit, most gastroenterologists endorse combination of 5ASA + CS for patients with active moderate-to-severe UC. Randomized controlled trials are needed to assess if 5ASA confer any benefit for these patients. | Shomron Ben-Horin Jane M Andrews Konstantinos H Katsanos Florian Rieder Flavio Steinwurz Konstantinos Karmiris Jae Hee Cheon Gordon William Moran Monica Cesarini Christian D Stone Doron Schwartz Marijana Protic Xavier Roblin Giulia Roda Min-Hu Chen Ofir Har-Noy Charles N Bernstein | 2017 | World Journal of Gastroenterology2017，23，16： | 3 |
| 3 | Optimising monitoring in the management of Crohn’s disease: A physician’s perspective显示文摘 | Pavol Papay Ana Ignjatovic Konstantinos Karmiris Heda Amarante Pal Milheller Brian Feagan Geert D’Haens Philippe Marteau Walter Reinisch Andreas Sturm Flavio Steinwurz Laurence Egan Julián Panés Edouard Louis Jean-Frédéric Colombel Remo Panaccione | 2013 | Journal of Crohn’s and Colitis2013，，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员